Home › Kanser sa Cervix › Virginia › Arlington
Pag-aaral pangklinika para sa Kanser sa Cervix sa Arlington, VA
16 pag-aaral para sa Kanser sa Cervix ang naghahanap ng mga kalahok sa mga site sa loob at paligid ng Arlington (sa loob ng humigit-kumulang 30 milya). Buksan ang pag-aaral upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.
Opisyal na teksto ng pag-aaral (English)
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
Nagre-recruitPhase 3
- Inova Schar Cancer Institute ( Site 5045), Fairfax · 11 mi ang layo
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Nagre-recruitPhase 1
- Virginia Cancer Specialists, Fairfax · 11 mi ang layo
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
Nagre-recruitPhase 1/2
- NEXT Oncology, Fairfax · 11 mi ang layo
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Nagre-recruitPhase 1
- Virginia Cancer Specialists, Fairfax · 11 mi ang layo
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
Nagre-recruitPhase 1
- NEXT Virginia, Fairfax · 11 mi ang layo
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
Nagre-recruitPhase 1
- Normunity Investigational Site, Fairfax · 11 mi ang layo
A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
Nagre-recruitPhase 1/2
- Clinical Trial Site, Fairfax · 11 mi ang layo
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Nagre-recruitPhase 1/2
- Virginia Cancer Specialists, Fairfax · 11 mi ang layo
A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix Cancer
Nagre-recruit
- Inova Health System, Fairfax · 11 mi ang layo
Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors
Nagre-recruitPhase 1
- NEXT Virginia, Fairfax · 11 mi ang layo
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Nagre-recruitPhase 1/2
- USO-Virginia Cancer Specialists, PC, Fairfax · 11 mi ang layo
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Nagre-recruitPhase 1
- Virginia Cancer Specialists, Fairfax · 11 mi ang layo
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Nagre-recruitPhase 1/2
- NEXT, Fairfax · 11 mi ang layo
Video-Based Patient Navigation to Support Cervical Cancer Screening Among Black Women
Nagre-recruit
- ISA Associates, Arlington
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
Nagre-recruitPhase 1
- Dren Investigational Site, Fairfax · 11 mi ang layo
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
Nagre-recruitPhase 1/2
- Research Site 102, Fairfax · 11 mi ang layo
- Research Site 112, Fairfax · 11 mi ang layo
Pag-aaral para sa Kanser sa Cervix sa ibang lungsod
- Houston, TX34 pag-aaral
- New York City, NY19 pag-aaral
- Nashville, TN19 pag-aaral
- Boston, MA18 pag-aaral
- Los Angeles, CA16 pag-aaral
- San Antonio, TX14 pag-aaral
- St. Louis, MO13 pag-aaral
- Dallas, TX13 pag-aaral
- Orlando, FL12 pag-aaral
- Chicago, IL12 pag-aaral
- Atlanta, GA11 pag-aaral
- Columbus, OH11 pag-aaral
Iba pang pag-aaral sa Arlington
- Non-Small Cell Lung Cancer104 pag-aaral
- Metastatic Cancer53 pag-aaral
- Colorectal Cancer52 pag-aaral
- Kanser (lahat ng uri)48 pag-aaral
- Kanser sa Suso47 pag-aaral
- Kanser sa Ovary46 pag-aaral
- Kanser sa Baga41 pag-aaral
- Kanser ng Endometrium39 pag-aaral
- Kanser sa Pancreas33 pag-aaral
- Squamous Cell Carcinoma ng Ulo at Leeg26 pag-aaral
- Small Cell Lung Cancer23 pag-aaral
- Kanser sa Tiyan20 pag-aaral
Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.